You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePipecuronium
Accession NumberDB01338
TypeSmall Molecule
GroupsApproved
DescriptionPipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.
Structure
Thumb
Synonyms
Pipecurium
Pipecuronium
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArduanNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pipecuronium bromide
52212-02-9
Thumb
  • InChI Key: TXWBOBJCRVVBJF-YTGGZNJNSA-L
  • Monoisotopic Mass: 760.313781786
  • Average Mass: 762.699
DBSALT000367
Categories
UNII1N3O74HM92
CAS number68399-58-6
WeightAverage: 602.8912
Monoisotopic: 602.477106492
Chemical FormulaC35H62N4O4
InChI KeyOWWLUIWOFHMHOQ-XGHATYIMSA-N
InChI
InChI=1S/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
IUPAC Name
4-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-13-(4,4-dimethylpiperazin-4-ium-1-yl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-4-yl]-1,1-dimethylpiperazin-1-ium
SMILES
[H][C@@]12C[C@@H]([[email protected]](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[[email protected]](OC(C)=O)[[email protected]](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1
Pharmacology
IndicationUsed as a muscle relaxant during anesthesia and surgical procedures.
Structured Indications Not Available
PharmacodynamicsPipecuronium is a nondepolarizing neuromuscular blocking agent. Neuromuscular blocking agents produce skeletal muscle paralysis by blocking neural transmission at the myoneural junction. The paralysis is selective initially and usually appears in the following muscles consecutively: levator muscles of eyelids, muscles of mastication, limb muscles, abdominal muscles, muscles of the glottis, and finally, the intercostal muscles and the diaphragm. Neuromuscular blocking agents have no clinically significant effect on consciousness or the pain threshold.
Mechanism of actionNondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents.
TargetKindPharmacological actionActionsOrganismUniProt ID
Neuronal acetylcholine receptor subunit alpha-2Proteinyes
antagonist
HumanQ15822 details
Muscarinic acetylcholine receptor M2Proteinunknown
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinunknown
antagonist
HumanP20309 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeDistribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB]
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AcetyldigitoxinPipecuronium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AclarubicinAclarubicin may increase the respiratory depressant activities of Pipecuronium.Investigational
AclidiniumAclidinium may increase the anticholinergic activities of Pipecuronium.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Alphacetylmethadol.Experimental, Illicit
AmbenoniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Ambenonium.Approved
AmikacinAmikacin may increase the respiratory depressant activities of Pipecuronium.Approved, Vet Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pipecuronium.Approved
annamycinannamycin may increase the respiratory depressant activities of Pipecuronium.Investigational
AnvirzelPipecuronium may increase the arrhythmogenic activities of Anvirzel.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Pipecuronium.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Pipecuronium.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pipecuronium.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Pipecuronium.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pipecuronium.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pipecuronium.Approved
BezitramideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Pipecuronium.Approved
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
Botulinum Toxin Type BPipecuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Butorphanol.Approved, Illicit, Vet Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Pipecuronium.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Carfentanil.Illicit, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Pipecuronium.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Chlorphenoxamine.Withdrawn
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Pipecuronium.Approved
CimetropiumPipecuronium may increase the anticholinergic activities of Cimetropium.Experimental
ClindamycinClindamycin may increase the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Codeine.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
CoumaphosThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Coumaphos.Vet Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pipecuronium.Approved
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational, Vet Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pipecuronium.Approved, Investigational
DaunorubicinDaunorubicin may increase the respiratory depressant activities of Pipecuronium.Approved
DecamethoniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Pipecuronium.Approved
DeslanosidePipecuronium may increase the arrhythmogenic activities of Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pipecuronium.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pipecuronium.Approved
DigitoxinPipecuronium may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinPipecuronium may increase the arrhythmogenic activities of Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Pipecuronium.Vet Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Diphenoxylate.Approved, Illicit
DonepezilThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Donepezil.Approved
DoxorubicinDoxorubicin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Pipecuronium is combined with DPDPE.Investigational
DronabinolPipecuronium may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Edrophonium.Approved
EluxadolinePipecuronium may increase the constipating activities of Eluxadoline.Approved
EpirubicinEpirubicin may increase the respiratory depressant activities of Pipecuronium.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Pipecuronium.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Pipecuronium.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Etorphine.Illicit, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fesoterodine.Approved
FramycetinFramycetin may increase the respiratory depressant activities of Pipecuronium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
GalantamineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pipecuronium.Approved
GeneticinGeneticin may increase the respiratory depressant activities of Pipecuronium.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Pipecuronium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Pipecuronium.Experimental
Ginkgo bilobaThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Glucagon recombinant.Approved
GlycopyrroniumPipecuronium may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pipecuronium.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Pipecuronium.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hydromorphone.Approved, Illicit
Hygromycin BHygromycin B may increase the respiratory depressant activities of Pipecuronium.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pipecuronium.Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Pipecuronium.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Pipecuronium.Approved
INNO-206INNO-206 may increase the respiratory depressant activities of Pipecuronium.Investigational
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pipecuronium.Approved
IsoflurophateThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Pipecuronium.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Pipecuronium.Approved, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Ketobemidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Levorphanol.Approved
LithiumLithium may increase the neuromuscular blocking activities of Pipecuronium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Lofentanil.Illicit
Magnesium hydroxideMagnesium hydroxide may increase the neuromuscular blocking activities of Pipecuronium.Approved
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Pipecuronium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Pipecuronium.Approved
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
MalathionThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Malathion.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pipecuronium.Approved
MefloquineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Memantine.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Pipecuronium.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Pipecuronium.Approved
MetixeneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Metixene.Approved
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Pipecuronium.Approved
MetrizamideMetrizamide may increase the respiratory depressant activities of Pipecuronium.Approved
MianserinMianserin may increase the anticholinergic activities of Pipecuronium.Approved
MinaprineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Morphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with N-butylscopolammonium bromide.Vet Approved
NabilonePipecuronium may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Nalbuphine.Approved
NeamineNeamine may increase the respiratory depressant activities of Pipecuronium.Experimental
NeomycinNeomycin may increase the respiratory depressant activities of Pipecuronium.Approved, Vet Approved
NeostigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Pipecuronium.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Normethadone.Approved, Illicit
NVA237The risk or severity of adverse effects can be increased when Pipecuronium is combined with NVA237.Investigational
OpiumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pipecuronium.Approved
OuabainPipecuronium may increase the arrhythmogenic activities of Ouabain.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pipecuronium.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pipecuronium.Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pipecuronium.Approved
ParomomycinParomomycin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pipecuronium.Approved
PethidineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pethidine.Approved
PhysostigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Physostigmine.Approved
PirarubicinPirarubicin may increase the respiratory depressant activities of Pipecuronium.Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pipecuronium.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Pipecuronium.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Piritramide.Investigational
PlicamycinPlicamycin may increase the respiratory depressant activities of Pipecuronium.Approved, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Pipecuronium.Approved
Potassium ChloridePipecuronium may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Pipecuronium.Approved, Investigational
ProcainamideProcainamide may increase the neuromuscular blocking activities of Pipecuronium.Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pipecuronium.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Pipecuronium.Approved
PropiverineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Propiverine.Investigational
PuromycinPuromycin may increase the respiratory depressant activities of Pipecuronium.Experimental
PyridostigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Pipecuronium.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Pipecuronium.Approved
QuinineQuinine may increase the neuromuscular blocking activities of Pipecuronium.Approved
RamosetronPipecuronium may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Remifentanil.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Pipecuronium.Approved
RivastigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipecuronium.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Scopolamine butylbromide.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Pipecuronium.Approved, Investigational
SisomicinSisomicin may increase the respiratory depressant activities of Pipecuronium.Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Solifenacin.Approved
SP1049CSP1049C may increase the respiratory depressant activities of Pipecuronium.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Pipecuronium.Approved, Vet Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Pipecuronium.Approved, Vet Approved
StreptozocinStreptozocin may increase the respiratory depressant activities of Pipecuronium.Approved
SufentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pipecuronium.Approved
TacrineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tapentadol.Approved
TetracyclineTetracycline may increase the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
TiotropiumPipecuronium may increase the anticholinergic activities of Tiotropium.Approved
TobramycinTobramycin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pipecuronium.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Topiramate.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
TramadolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Pipecuronium.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pipecuronium.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pipecuronium.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pipecuronium.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Pipecuronium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pipecuronium.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Pipecuronium.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Pipecuronium.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Pipecuronium.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Vecuronium.Approved
ZorubicinZorubicin may increase the respiratory depressant activities of Pipecuronium.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM03AC06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8906
Blood Brain Barrier+0.6351
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.8501
P-glycoprotein inhibitor IInhibitor0.7487
P-glycoprotein inhibitor IIInhibitor0.5983
Renal organic cation transporterNon-inhibitor0.7112
CYP450 2C9 substrateNon-substrate0.8587
CYP450 2D6 substrateNon-substrate0.7823
CYP450 3A4 substrateSubstrate0.7542
CYP450 1A2 substrateNon-inhibitor0.9065
CYP450 2C9 inhibitorNon-inhibitor0.9152
CYP450 2D6 inhibitorNon-inhibitor0.9059
CYP450 2C19 inhibitorNon-inhibitor0.8819
CYP450 3A4 inhibitorNon-inhibitor0.8232
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9438
Ames testNon AMES toxic0.752
CarcinogenicityNon-carcinogens0.9083
BiodegradationNot ready biodegradable0.9272
Rat acute toxicity2.6004 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9193
hERG inhibition (predictor II)Non-inhibitor0.7647
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility9.5e-05 mg/mLALOGPS
logP-1.4ALOGPS
logP-5.3ChemAxon
logS-6.8ALOGPS
pKa (Strongest Basic)5.31ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area59.08 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity193.04 m3·mol-1ChemAxon
Polarizability72.22 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid esters
Direct ParentSteroid esters
Alternative Parents
Substituents
  • Steroid ester
  • Androstane-skeleton
  • N-alkylpiperazine
  • N-methylpiperazine
  • Cyclohexylamine
  • Piperazine
  • 1,4-diazinane
  • Acetate salt
  • Quaternary ammonium salt
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic cation
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA2
Uniprot ID:
Q15822
Molecular Weight:
59764.82 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Karpati E, Biro K, Kukorelli T: [Investigation of neuromuscular blocking agents at Richter Ltd]. Acta Pharm Hung. 2002;72(1):37-48. [PubMed:12426786 ]
  3. Kiss JP, Windisch K, Balla A, Sershen H, Lajtha A: Dual effect of DMPP on the resting release of noradrenaline from rat hippocampal slices. Brain Res Bull. 1997;43(3):257-62. [PubMed:9227834 ]
  4. Torocsik A, Oberfrank F, Sershen H, Lajtha A, Nemesy K, Vizi ES: Characterization of somatodendritic neuronal nicotinic receptors located on the myenteric plexus. Eur J Pharmacol. 1991 Sep 24;202(3):297-302. [PubMed:1748153 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Karpati E, Biro K, Kukorelli T: [Investigation of neuromuscular blocking agents at Richter Ltd]. Acta Pharm Hung. 2002;72(1):37-48. [PubMed:12426786 ]
  2. Zappi L, Song P, Nicosia S, Nicosia F, Rehder K: Do pipecuronium and rocuronium affect human bronchial smooth muscle? Anesthesiology. 1999 Dec;91(6):1616-21. [PubMed:10598601 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Karpati E, Biro K, Kukorelli T: [Investigation of neuromuscular blocking agents at Richter Ltd]. Acta Pharm Hung. 2002;72(1):37-48. [PubMed:12426786 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Simon G, Biro K, Karpati E, Tuba Z: The effect of the steroid muscle relaxant pipecurium bromide on the acetylcholinesterase activity of red blood cells in vitro. Arzneimittelforschung. 1980;30(2a):360-3. [PubMed:6248079 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:08 / Updated on December 08, 2016 11:11